Watson Jessica, Whiting Penny, Salisbury Chris, Banks Jonathan, Hamilton Willie
Centre for Academic Primary Care, University of Bristol, Bristol, UK
Bristol Population Health Science Institute, University of Bristol, Bristol, UK.
BMJ Open. 2020 Oct 15;10(10):e036027. doi: 10.1136/bmjopen-2019-036027.
Identification of patients at increased mortality risk is important in the context of increasing multimorbidity and an ageing population, to help facilitate the planning and delivery of services. The aim of this study was to examine 1-year all-cause mortality in a cohort of primary care patients in whom inflammatory markers including C reactive protein (CRP), erythrocyte sedimentation rate (ESR) and plasma viscosity (PV), had been tested.
Observational cohort study using general practitioner Electronic Health Records from the Clinical Practice Research Datalink, with linkage to Office for National Statistics (ONS) Death Registry.
UK Primary Care.
159 325 patients with inflammatory marker tests done in 2014 and 39 928 age, sex and practice-matched controls without inflammatory marker testing. ONS Death registry data were available for 109 966 participants.
One-year mortality in those with raised inflammatory markers compared with normal inflammatory markers and untested controls. Subanalyses stratified 1-year mortality by age group, gender and cause of death.
Patients with a raised inflammatory marker (n=47 797) had an overall 1-year all-cause mortality of 6.89%, compared with 1.41% in those with normal inflammatory markers (p<0.001) and 1.62% in untested controls. A raised CRP is associated with the highest mortality rate at 8.76% compared with 4.99% for ESR and 4.66% for PV. One-year mortality is higher in men with a raised inflammatory marker compared with women (9.78% vs 5.29%). The C-statistic of a simple mortality prediction model containing age, sex and CRP test result is 0.89.
Inflammatory markers are a strong predictor of all-cause mortality in primary care, with a C-statistic comparable to several previously developed frailty indices. Future research should consider the added value of CRP testing, in combination with other risk factors, to improve prediction of mortality in primary care. Evidence- based interventions for frailty are needed alongside predictive tools.
在多重疾病发生率不断上升和人口老龄化的背景下,识别死亡风险增加的患者对于帮助促进服务规划和提供至关重要。本研究的目的是调查一组接受过包括C反应蛋白(CRP)、红细胞沉降率(ESR)和血浆粘度(PV)在内的炎症标志物检测的初级保健患者的1年全因死亡率。
利用临床实践研究数据链中的全科医生电子健康记录进行观察性队列研究,并与国家统计局(ONS)死亡登记处建立联系。
英国初级保健。
2014年进行炎症标志物检测的159325名患者以及39928名年龄、性别和执业情况匹配但未进行炎症标志物检测的对照者。109966名参与者可获取ONS死亡登记数据。
炎症标志物升高者与炎症标志物正常者及未检测对照者的1年死亡率。亚组分析按年龄组、性别和死亡原因对1年死亡率进行分层。
炎症标志物升高的患者(n = 47797)1年全因死亡率总体为6.89%,而炎症标志物正常者为1.41%(p < 0.001),未检测对照者为1.62%。CRP升高与最高死亡率相关,为8.76%,而ESR为4.99%,PV为4.66%。炎症标志物升高的男性1年死亡率高于女性(9.78%对5.29%)。包含年龄、性别和CRP检测结果的简单死亡率预测模型的C统计量为0.89。
炎症标志物是初级保健中全因死亡率的有力预测指标,其C统计量与先前开发的几个衰弱指数相当。未来的研究应考虑CRP检测与其他风险因素相结合的附加价值,以改善初级保健中死亡率的预测。除了预测工具外,还需要基于证据的衰弱干预措施。